posted
NEWS OUT! GenoMed Launches National Marketing Campaign. This should raise eyebrows. Market Awareness! They are on radios nationwide and newspapers. This company will fly again.
GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. After establishing the superiority of a treatment protocol in clinical trials, the Company charges patients a reasonable license fee to use the protocol, which is patented. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company's protocol continues to be successful, GenoMed will market it beginning next year. GenoMed is currently marketing its protocol for delaying or even preventing complications of high blood pressure and diabetes, which affect 80 million Americans, as well as emphysema, which affects another 3 million people in the U.S., as well as 60 million smokers. http://www.genomedics.com David W. Moskowitz, MD, MA, FACP of GenoMed Inc., +1-314-977-0115, dwmoskowitz@genomedics.com
ST. LOUIS, Jun 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM(TM) (Disease Management) company that uses its expertise in medical genomics to improve clinical outcomes, announced today that it has hired a Chief Scientific Officer and launched its large-scale genotyping project with Genome Quebec.
Dr. Paula M. Hempen was hired as Chief Scientific Officer. She earned her PhD in the Department of Microbiology and Immunology at the University of Kentucky, where she co-authored four papers on the regulation of the immunoglobulin receptor gene. She then completed a three-year post-doc on the genetics of pancreatic cancer at Johns Hopkins University School of Medicine, where she co-authored another five papers. She has extensive teaching experience at the high school, undergraduate, and graduate school levels.
Said Dr. David Moskowitz, GenoMed's CEO and Chairman, "I'm delighted to have Dr. Hempen join us full-time, now that we are financially healthy enough to make use of her many talents. She first expressed her interest in GenoMed nearly two years ago. Her experience in cancer genetics, her down-to-earth manner, her perseverance, and her skill at explaining complex subjects will be extremely helpful. She and our Chief Technical Officer Andy O'Guin are already constructing a larger Disease GeneNet for us to use to capture cancer-causing genes."
GenoMed also recently sent 22,000 SNPs to Genome Quebec to begin its large-scale genotyping project to find genes which cause common cancers. Any genes which GenoMed finds will be patented and used as an early warning system to enable early, cost-effective screening of patients at high risk of cancer. These cancer genes will thus have diagnostic value almost immediately. But as drug targets, cancer genes may prove difficult. For example, no drugs have yet been designed against BRCA 1 or 2, the breast cancer genes discovered a decade ago.
About GenoMed
GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. In addition to looking for new disease- predisposition genes, the Company is currently marketing its treatment to prevent kidney failure due to diabetes and high blood pressure, and to delay emphysema. GenoMed is currently conducting a global trial against West Nile virus encephalitis and other lethal viruses.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatments continue to be as effective as they have been so far; (b) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
SOURCE GenoMed, Inc.
David W. Moskowitz, MD, MA, FACP of GenoMed Inc., +1-314-652-0500, dwmoskowitz@genomedics.com http://www.genomedics.com
Copyright (C) 2004 PR Newswire. All rights reserved
America`s First Two WNV Encephalitis Cases of 2004 Respond Promptly to GenoMed`s Treatment
June 10, 2004 13:34:00 (ET)
ST. LOUIS, Jun 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that the country's second case of West Nile virus encephalitis has responded promptly to its treatment approach. So far, GenoMed's treatment is showing a 100% response rate among 13 immunocompetent patients. The sooner the treatment is instituted, the more rapid and complete the response.
The first case involved a 79-year-old man treated in Portsmouth, Ohio (see April press releases). The latest case involves a 67-year-old man from Marion, Arkansas. What makes this second case especially interesting is that the gentleman was immunosuppressed until just a few days before receiving GenoMed's treatment. He took 30 mg of Prednisone for 11 years because of arthritis. Despite becoming acutely ill with West Nile virus encephalitis, his physicians were nevertheless able to wean his Prednisone dose down to 5 mg a day. After 4 days on this dose, he began GenoMed's treatment on Monday, June 7th, and within 24 hours he was dramatically improved.
For the previous 14 days, he had had a headache, with nausea, vomiting, no appetite, lethargy, irritability, and disorientation. He had no interest in getting out of bed, and had no idea where he was. Within 24 hours of starting GenoMed's treatment, by Tuesday afternoon, June 8th, he sat up in bed, asked to get out of bed for the first time in two weeks, and eagerly ate his whole supper. He was oriented for the first time in two weeks, and said he felt "70% better".
GenoMed's record is now 13-0 for immunocompetent patients, including 2 patients who began treatment months after their episode of West Nile virus encephalitis. When treated during their episode of WNV encephalitis, patients have responded within 24 hours, as this patient did. Such a rapid response is extremely unusual for WNV encephalitis, which can take weeks to resolve.
GenoMed's sole failure occurred in a woman with chronic leukemia treated last September 2003. The company therefore recommends other treatments for immunosuppressed patients. The results of Dr. Moskowitz's first eight patients, including the patient with CLL, will be published next month in a peer-reviewed medical journal.
GenoMed's goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" link at http://www.genomedics.com .
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and for delaying emphysema. If GenoMed's clinical trial for WNV encephalitis proves successful, the Company will charge a modest licensing fee beginning in 2005 for use of its protocol, which is patent-pending.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis remains effective; (b) whether our server holds up to heavy demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement
SOURCE GenoMed, Inc.
David W. Moskowitz, MD, MA, FACP of GenoMed Inc., +1-314-652-0500, dwmoskowitz@genomedics.com http://www.genomedics.com
Copyright (C) 2004 PR Newswire. All rights reserved
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
